Before you can access ASH's online program, you must agree to the following:
Last updated January 16, 2009. Please note that this site represents the latest program changes
and differs from the print version in some details.

621.P1.16 Hodgkin’s Lymphoma - Biology, Excluding Therapy Poster I

Saturday, December 6, 2008: 5:30 PM-7:30 PM
Hall A (Moscone Center)
A Novel Hodgkin Lymphoma Cell Line (KHL) Established from An Untreated Patient

Ta-Chih Liu1*, Yuan-Shiang Kao2*, Rachael Demuth2*, Nina Mathews2*, Carmen Espinoza2* and Jan-Gowth Chang1*

1Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
2Department of Pathology, Louisiana State University Health Sciences Center, New Orleans, LA

Quality Control of PET Imaging in a Multicentre Phase III Trial (RAPID) Involving Randomisation of Patients with Stages IA and IIA Hodgkin Lymphoma Who Are PET ‘negative’ after 3 Cycles of ABVD Chemotherapy

Sally F Barrington1*, Michael J O'Doherty1*, Jane MacKewn1*, Paul Schleyer1*, Wendi Qian2*, Philippa Patrick2*, Timothy Illidge3, Ruth Pettengell4*, Peter Hoskin5*, Barry Hancock6* and John Radford3*

1PET Imaging Centre at St Thomas', Kings College London Division of Imaging, London, United Kingdom
2Cancer Research UK and UCL Clinical Trials Centre, London, United Kingdom
3Christie Hospital and the University of Manchester, Manchester, United Kingdom
4St Georges Hospital, London, United Kingdom
5Mount Vernon Hospital, United Kingdom
6Weston Park Hospital, Sheffield, United Kingdom

Early FDG-PET Scan Confirms Its Prognostic Impact Also in Localized Stage, ABVD Treated Hodgkin Lymphoma Patients

Luigi Rigacci1*, Benedetta Puccini1*, Francesco Merli2*, Caterina Stelitano3*, Patrizia Pregno, MD4*, Chiara Fraulini5*, Flavia Salvi6*, Rita Emili7*, Ida Capodanno2*, Umberto Vitolo4, Teodoro Chisesi5*, Alessandro Levis6, Anna Marina Liberati7 and Alberto Bosi1*

1Hematology, Azienda Ospedaliero Universitaria Careggi, Florence, Italy
2Hematology, Ospedale Reggio Emilia, Reggio Emilia, Italy
3Ematologia, Ospedale Reggio Calabria
4S.C.D.O. Ematologia 2, A.O.U San Giovanni Battista
5Hematology, Ospedale Venezia, Venice
6Hematology, Ospedale Alessandria
7Hematology, Ospedale Perugia

Genomic Alterations in Hodgkin's and Reed/Sternberg (HRS) Cells at Disease Onset Reveals Distinct Signatures for Chemosensitive and Primary Refractory Hodgkin’s Lymphoma

Marilyn L. Slovak1, Victoria Bedell1*, Dolores Bobadilla1*, Norma J Nowak2*, Maria L. Delioukina3, Lawrence M. Weiss1*, David Smith4* and Stephen J. Forman3

1Pathology, City of Hope, Duarte, CA
2Cancer Prevention, Roswell Park Cancer Institute, Buffalo, NY
3Hematology/HCT, City of Hope, Duarte, CA
4Information Sciences, City of Hope, Duarte, CA

Not All Positive Interim PET/CT Scans Are Reliably Predictive for Progression Free Survival in Hodgkin Lymphoma (HL) Patients. A Proposed Model for a Functional Scoring Scale

Eldad J. Dann, MD1, Ada Tamir, PhD2*, Ron Epelbaum, MD3*, Irit Avivi, MD1*, Menachem Ben-Shachar, MD3*, Diana Gaitini, MD4*, Jacob M. Rowe, MD5 and Rachel Bar-Shalom, MD6*

1Department of Hematology & Bone Marrow Transplantation, Rambam Medical Center, Haifa, Israel
2Bruce Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel
3Department of Oncology, Rambam Medical Center, Haifa, Israel
4Department of Radiology, Rambam Medical Center, Haifa, Israel
5Hematology and Bone Marrow Transplantation, Rambam Health Care Campus and Technion, Israel Institute of Technology, Haifa, Israel., Haifa, Israel
6Department of Nuclear Medicine, Rambam Medical Center, Haifa, Israel

Early Interim FDG-PET Scan Predicts Outcome in Non-Bulky Limited Stage Hodgkin Lymphoma, but may Not Guide Use of Consolidative Radiotherapy

Jeffrey A. Barnes, M.D.1*, Ann S. LaCasce, MD2, Christiana E. Toomey1*, Ephraim Hochberg1, Alfred I. Lee1*, George P. Canellos, MD2 and Jeremy S. Abramson, MD1

1Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA
2Dana-Farber Cancer Institute, Boston, MA

Prospective Evaluation of the International Prognostic Score (IPS) in All Stages of Hodgkin's Lymphoma Treated with ABVD Plus Involved-Field Radiotherapy (IFRT)

Santiago Pavlovsky, Claudia Corrado*, Miguel A Pavlovsky*, Virginia Prates*, Lucia Zoppegno*, Mario Giunta*, Ider Cerutti*, Elsa Palomino*, Graciela Avila* and Francisco Lastiri*

GATLA, Grupo Argentino Tratamiento de Leucemia Aguda, Buenos Aires, Argentina

Quality of Life in a 2-Year Follow-up: Signs of PNP Predicting Cognitive Functioning in Survivors Treated in the HD10-12 Trials of the German Hodgkin Study Group (GHSG)

Teresa Halbsguth1*, Horst Mueller1*, Hans-Henning Flechtner2*, Corinne Brillant1*, Karolin Behringer1*, Thomas Schober1*, Hiltrud Nisters-Backes1*, Andreas Engert1 and Peter Borchmann1*

1First department of Internal Medicine / German Hodgkin Study Group (GHSG), University of Cologne, Cologne, Germany
2Otto-von-Guericke-University Magdeburg, Magdeburg, Germany

Analysis of FDG PET Diffuse Bone Marrow Uptake in Staging of Hodgkin’s Disease: A Reflect of Disease Infiltration or Just Inflammation?

Pierre Y Salaun, MD1*, Thomas Gastine, MD2*, Loic Campion, MD3*, Pierre Cambefort, MD1*, Caroline Bodet-Milin, MD4*, Anne Moreau, MD2*, Steven Le Gouil, MD2*, Jean-Luc Harousseau5 and Françoise Kraeber-Bodéré, MD, PhD6*

1Nuclear Medicine, University Hospital of Brest, Brest, France
2Hematology, University Hospital of Nantes, Nantes, France
3Statistics, Centre Gauducheau, Saint-Herblain, France
4Place Alexis Ricordeau, University Hospital of Nantes, Nantes, France
5Hôpital Hôtel Dieu, Nantes, France
6Nuclear medecine, CHU de Nantes, Nantes, France

Childhood infection experience and risk of Young Adult Hodgkin Lymphoma

Wendy Cozen, D., O., M.P.H.1*, Ann S. Hamilton, P.hD.2*, Peng Zhao, M.S.2*, Muhammed Towhid Salam, M.B.B.S2*, Dennis M. Deapen, DR.PH.2*, Bharat N. Nathwani, MD3, Lawrence M. Weiss4* and Thomas M. Mack1*

1Preventive Medicine and Pathology, Keck School of Medicine and Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA
2Preventive Medicine, Keck School of Medicine and Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA
3Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, CA
4City of Hope National Med. Ctr., Duarte, CA

Differential Effects of TRAFs in the Activation of NF-KappB in Hodgkin’s Lymphoma Cells

Feng Guo, MD, PhD1*, Zi-Xing Chen, MD2*, Aining Sun, MD3*, Peng Zhou, MS1* and Wenjuan Wang, MS3*

1Central Lab, The First Affiliated Hospital of Soochow University, Suzhou, China
2Jiangsu Inst. of Hematology, Suzhou, China
3Dept. of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China

miRNA Profiling of B Cell Subsets: Specific miRNA Profile for Germinal Center B Cells with a Marked Variation Between Centroblast and Centrocytes

Lu Ping Tan1*, Miao Wang1*, Jan-Lukas Robertus1*, Rikst Nynke Schakel1*, Johan H Gibcus1*, Arjan Diepstra1*, Geert Harms1*, Suat Cheng Peh2*, Rogier M Reijmers3*, Steven T Pals3*, Lydia Visser1*, Philip Kluin1, Sibrand Poppema1, Bart-Jan Kroesen4* and Anke van den Berg1*

1Department of Pathology and Laboratory Medicine, University Medical Center Groningen, Groningen, Netherlands
2Department of Pathology, University Malaya Medical Center, Kuala Lumpur, Malaysia
3Department of Pathology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands
4Department of Medical Biology, University Medical Center Groningen, Groningen, Netherlands

Validation of the International Harmonization Project (IHP) Guidelines in Early Stage Hodgkin Lymphoma (HL) Treated with Adriamycin, Vinblastine and Gemcitabine (AVG) (CALGB 50203): Early Results

Lale Kostakoglu, MD, MPH1*, David J. Straus, MD2, Heiko Schöder, MD3*, Ann S. LaCasce, MD4, Nancy L Bartlett, MD5, Nathan Hall, MD, PhD6*, Jeffrey L Johnson, PhD7*, Sin-Ho Jung, PhD7*, George P. Canellos, MD8, Lawrence H Schwartz, MD3* and Bruce D. Cheson, MD9

1Radiology, Mount Sinai Medical Center, New York, NY
2Medicine, MSKCC, New York, NY
3Radiology, Memorial Sloan Kettering Cancer Center, New York, NY
4Dana-Farber Cancer Inst., Boston, MA
5Washington University School of Medicine, Saint Louis, MO
6Radiology, Ohio State University, Columbus, OH
7CALGB Statistical Office, Duke University Medical Center, Durham, NC
8Dana-Farber Cancer Institute, Boston, MA
9Lombardi Cancer Ctr., Georgetown Univ. Hosp., Washington, DC

A High Throughput Experimental Approach to Identify miRNA Target Genes in Hodgkin Lymphoma

Lu Ping Tan1*, Erwin Seinen2*, Gerben Duns3*, Debora Jong1*, Rikst Nynke Schakel1*, Geert Harms1*, Ody Sibon2*, Klaas Kok3*, Sibrand Poppema1, Bart-Jan Kroesen1* and Anke van den Berg1*

1Department of Pathology and Laboratory Medicine, University Medical Center Groningen, Groningen, Netherlands
2Department of Cell Biology/Radiation and Stress Cell Biology, University Medical Center Groningen, Groningen, Netherlands
3Department of Genetics, University Medical Center Groningen, Groningen, Netherlands

Quantitative Proteomic Identification of Novel Diagnostic Biomarkers and Therapeutic Targets for Classical Hodgkin Lymphoma

Mihaela D. Chiselite1*, Damian Fermin1*, Venkatesha Basrur1*, Kevin P. Conlon1*, Charles Seiler1*, Ian Waxman2*, Mitchell S. Cairo2*, Kojo S.J. Elenitoba-Johnson1 and Megan S. Lim1

1Department of Pathology, University of Michigan Medical School, Ann Arbor, MI
2Department of Pediatrics, Pathology and Medicine, Morgan Stanley Children's Hospital of New-York Presbyterian, Columbia University, New York City, NY

Prognostic Value of Immunohistochemical Angiogenic and Invasion Markers in Hodgkin Lymphoma

Francisco Mestre1*, Antonio Gutierrez, MD2*, Rafael Ramos3*, M. Casasus1*, C. Nicolau1*, Jordi Martinez2*, Juan Besalduch4, Julio Rifa5*, Juan Fernando Garcia6* and Jose Rodriguez7*

1Radiotherapy, University Hospital Son Dureta, Palma, Spain
2Dept. of Hematology, Hospital Universitario Son Dureta, Palma, Spain
3Pathology, University Hospital Son Dureta
4Hematology, University Hospital Son Dureta, Spain, Spain
5Oncology, University Hospital Son Dureta
6CNIO
7Oncology, University Hospital Gregorio Marañon

*signifies non-member of ASH